Merck & Co Inc
SGO:MRK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Merck & Co Inc
SGO:MRK
|
US |
|
Focus Minerals Ltd
OTC:FCSUF
|
AU |
Intrinsic Value
The intrinsic value of 
Merck & Co Inc (MRK) under the Base Case is 81.8 USD per share.
Compared with the current market price of 109.8 USD, the stock appears
Overvalued by 26% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Merck Does
Merck & Co. is a global drug company that makes prescription medicines, vaccines, and animal health products. Its best-known business is developing and selling branded drugs for cancer, infectious disease, diabetes, and other serious conditions. It also sells vaccines and medicines used by veterinarians and livestock producers.
- Headquarters
- United States of America US
- Employees
- 75 000
- IPO date
- Jan 1, 1941
Merck & has a wide economic moat
Legal protection for Merck’s medicines prevents rivals from freely selling copies, allowing it to earn more than it could in a market filled with cheaper alternatives. Its protected treatments span cancer, vaccines and other diseases, so this protection extends beyond a single medicine.
Read the full moat analysisLatest Earnings Call
Merck raised its revenue outlook as LIPFENDRA approval and earlier-than-expected pipeline readouts strengthened management’s confidence in diversifying beyond KEYTRUDA.
- EPS
- −$0.13
- Expected
- −$0.26
- Surprise
- +50.0%
Revenue & Expenses Breakdown
Merck & Co Inc
Earnings Waterfall
Merck & Co Inc
The intrinsic value for Merck & Co Inc (MRK) under the Base Case is 81.8 USD.
Compared with the current market price of 109.8 USD, the stock appears Overvalued by 26% .